Targeting noncoding RNAs to treat atherosclerosis

Miron Sopić, Sandra Vladimirov, Jelena Munjas, Tijana Mitić, Ignacio Fernando Hall, Amela Jusic, Dusan Ruzic, Yvan Devaux*, AtheroNET COST Action CA21153

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.

Original languageEnglish
JournalBritish Journal of Pharmacology
DOIs
Publication statusE-pub ahead of print - 8 May 2024

Fingerprint

Dive into the research topics of 'Targeting noncoding RNAs to treat atherosclerosis'. Together they form a unique fingerprint.

Cite this